{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:51:32Z","timestamp":1793987492043,"version":"4.8.0"},"reference-count":179,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Antimicrob Resist Infect Control"],"DOI":"10.1186\/s13756-025-01518-5","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T15:47:46Z","timestamp":1739288866000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Global trends of ceftazidime\u2013avibactam resistance in gram-negative bacteria: systematic review and meta-analysis"],"prefix":"10.1186","volume":"14","author":[{"given":"Yang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Sholeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LunDi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matin Zafar","family":"Shakourzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoumeh","family":"Beig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil","family":"Azizian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"key":"1518_CR1","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s40121-021-00507-6","volume":"10","author":"A Soriano","year":"2021","unstructured":"Soriano A, Carmeli Y, Omrani AS, Moore LS, Tawadrous M, Irani P. Ceftazidime-avibactam for the treatment of serious Gram-negative infections with limited treatment options: a systematic literature review. Infect Dis Ther. 2021;10:1989\u20132034.","journal-title":"Infect Dis Ther"},{"key":"1518_CR2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jgar.2019.12.009","volume":"22","author":"Y Wang","year":"2020","unstructured":"Wang Y, Wang J, Wang R, Cai Y. Resistance to ceftazidime\u2013avibactam and underlying mechanisms. J Glob Antimicrob Resist. 2020;22:18\u201327.","journal-title":"J Glob Antimicrob Resist"},{"issue":"4","key":"1518_CR3","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ijantimicag.2018.07.004","volume":"52","author":"H Zhong","year":"2018","unstructured":"Zhong H, Zhao X-Y, Zhang Z-L, Gu Z-C, Zhang C, Gao Y, et al. Evaluation of the efficacy and safety of ceftazidime\/avibactam in the treatment of Gram-negative bacterial infections: a systematic review and meta-analysis. Int J Antimicrob Agents. 2018;52(4):443\u201350.","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"1518_CR4","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/S1473-3099(16)30265-1","volume":"16","author":"Y Carmeli","year":"2016","unstructured":"Carmeli Y, Armstrong J, Newell P, Stone G, Wardman A. Ceftazidime-avibactam in ceftazidime-resistant infections. Lancet Infect Dis. 2016;16(9):997\u20138.","journal-title":"Lancet Infect Dis"},{"key":"1518_CR5","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00047-19","author":"K Bush","year":"2020","unstructured":"Bush K, Bradford PA. Epidemiology of \u03b2-lactamase-producing pathogens. Clin Microbiol Rev. 2020. https:\/\/doi.org\/10.1128\/cmr.00047-19.","journal-title":"Clin Microbiol Rev"},{"key":"1518_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/S0213-005X(14)70168-5","volume":"32","author":"L Mart\u00ednez-Mart\u00ednez","year":"2014","unstructured":"Mart\u00ednez-Mart\u00ednez L, Gonz\u00e1lez-L\u00f3pez JJ. Carbapenemases in Enterobacteriaceae: types and molecular epidemiology. Enferm Infecc Microbiol Clin. 2014;32:4\u20139.","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"9","key":"1518_CR7","doi-asserted-by":"publisher","first-page":"e00447","DOI":"10.1128\/aac.00447-22","volume":"66","author":"CA Hobson","year":"2022","unstructured":"Hobson CA, Pierrat G, Tenaillon O, Bonacorsi S, Bercot B, Jaouen E, et al. Klebsiella pneumoniae carbapenemase variants resistant to ceftazidime-avibactam: an evolutionary overview. Antimicrob Agents Chemother. 2022;66(9):e00447-e522.","journal-title":"Antimicrob Agents Chemother"},{"key":"1518_CR8","doi-asserted-by":"publisher","first-page":"651","DOI":"10.2165\/11318430-000000000-00000","volume":"70","author":"C Bebrone","year":"2010","unstructured":"Bebrone C, Lassaux P, Vercheval L, Sohier J-S, Jehaes A, Sauvage E, et al. Current challenges in antimicrobial chemotherapy: focus on \u03b2-lactamase inhibition. Drugs. 2010;70:651\u201379.","journal-title":"Drugs"},{"key":"1518_CR9","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02569-17","author":"JA Karlowsky","year":"2018","unstructured":"Karlowsky JA, Kazmierczak KM, Bouchillon SK, de Jonge BL, Stone GG, Sahm DF. In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa collected in Asia-Pacific countries: results from the INFORM global surveillance program, 2012 to 2015. Antimicrob Agents Chemother. 2018. https:\/\/doi.org\/10.1128\/aac.02569-17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"1518_CR10","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.3390\/antibiotics10091126","volume":"10","author":"GL Daikos","year":"2021","unstructured":"Daikos GL, da Cunha CA, Rossolini GM, Stone GG, Baillon-Plot N, Tawadrous M, et al. Review of ceftazidime-avibactam for the treatment of infections caused by Pseudomonas aeruginosa. Antibiotics. 2021;10(9):1126.","journal-title":"Antibiotics"},{"key":"1518_CR11","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s40265-018-0902-x","volume":"78","author":"M Shirley","year":"2018","unstructured":"Shirley M. Ceftazidime-avibactam: a review in the treatment of serious gram-negative bacterial infections. Drugs. 2018;78:675\u201392.","journal-title":"Drugs"},{"issue":"14","key":"1518_CR12","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1001\/jama.2015.12480","volume":"314","author":"AY Guh","year":"2015","unstructured":"Guh AY, Bulens SN, Mu Y, Jacob JT, Reno J, Scott J, et al. Epidemiology of carbapenem-resistant Enterobacteriaceae in 7 US communities, 2012\u20132013. JAMA. 2015;314(14):1479\u201387.","journal-title":"JAMA"},{"issue":"5","key":"1518_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106344","volume":"57","author":"L Scudeller","year":"2021","unstructured":"Scudeller L, Righi E, Chiamenti M, Bragantini D, Menchinelli G, Cattaneo P, et al. Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli. Int J Antimicrob Agents. 2021;57(5): 106344.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"1518_CR14","doi-asserted-by":"publisher","first-page":"e02603","DOI":"10.1128\/spectrum.02603-21","volume":"10","author":"Y Chen","year":"2022","unstructured":"Chen Y, Huang H-B, Peng J-M, Weng L, Du B. Efficacy and safety of ceftazidime-avibactam for the treatment of carbapenem-resistant Enterobacterales bloodstream infection: a systematic review and meta-analysis. Microbiol Spect. 2022;10(2):e02603-e2621.","journal-title":"Microbiol Spect"},{"key":"1518_CR15","unstructured":"Wayne A. Clinical and Laboratory Standards Institute; CLSI. 2022. Performance standards for antimicrobial susceptibility testing 20th Informational Supplement CLSI document. 2022."},{"key":"1518_CR16","unstructured":"EUCAST T. European committee on antimicrobial susceptibility testing. Breakpoint Tables for Interpretation of MICs and Zone Diameters Version 100. 2020."},{"key":"1518_CR17","unstructured":"Schwarzer GJR. Meta: An R package for meta-analysis. 2007;7(3):40\u20135."},{"key":"1518_CR18","unstructured":"Team RCJhwR-po. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2013."},{"key":"1518_CR19","doi-asserted-by":"crossref","unstructured":"Cochran WGJB. Some methods for strengthening the common \u03c7 2 tests. 1954;10(4):417\u201351.","DOI":"10.2307\/3001616"},{"issue":"11","key":"1518_CR20","first-page":"1539","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP. Thompson SGJSim. Quantifying heterogeneity in a meta-analysis. 2002;21(11):1539\u201358.","journal-title":"Quantifying heterogeneity in a meta-analysis"},{"key":"1518_CR21","first-page":"2022","volume-title":"Antimicrobial activity of ceftazidime-avibactam and comparators against Pseudomonas aeruginosa and Enterobacterales collected in Croatia","author":"V Ad\u00e1mkov\u00e1","year":"2019","unstructured":"Ad\u00e1mkov\u00e1 V, Marekovi\u0107 I, Szab\u00f3 J, Pojnar L, Billov\u00e1 S, Horvat Herceg S, et al. Antimicrobial activity of ceftazidime-avibactam and comparators against Pseudomonas aeruginosa and Enterobacterales collected in Croatia. ATLAS Surveillance Program: Czech Republic, Hungary, Poland, Latvia and Lithuania; 2019. p. 2022."},{"key":"1518_CR22","doi-asserted-by":"publisher","first-page":"3427972","DOI":"10.1155\/2024\/3427972","volume":"2024","author":"F Ahmed","year":"2024","unstructured":"Ahmed F, Abraham B, Kamal Saeed N, Mohamed Naser H, Sridharan K. Retrospective tertiary care-based cohort study on clinical characteristics and outcomes of ceftazidime-avibactam-resistant carbapenem-resistant klebsiella pneumoniae infections. Crit Care Res Prac. 2024;2024:3427972.","journal-title":"Crit Care Res Prac"},{"key":"1518_CR23","doi-asserted-by":"crossref","unstructured":"Alfouzan W, Dhar R, Nicolau DP. In vitro activity of newer and conventional antimicrobial agents, including fosfomycin and colistin, against selected gram-negative Bacilli in Kuwait. 2018.","DOI":"10.3390\/pathogens7030075"},{"key":"1518_CR24","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00113-18","author":"SS Almarzoky Abuhussain","year":"2018","unstructured":"Almarzoky Abuhussain SS, Kuti JL, Nicolau DP. Antibacterial activity of human simulated epithelial lining fluid concentrations of ceftazidime-avibactam alone or in combination with amikacin inhale (BAY41-6551) against carbapenem-resistant Pseudomonas aeruginosa and Klebsiella pneumoniae. Antimicrob Agents Chemother. 2018. https:\/\/doi.org\/10.1128\/aac.00113-18.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"1518_CR25","first-page":"203","volume":"15","author":"AM Alnimr","year":"2020","unstructured":"Alnimr AM, Alamri AM. Antimicrobial activity of cephalosporin-beta-lactamase inhibitor combinations against drug-susceptible and drug-resistant Pseudomonas aeruginosa strains. J Taibah Univ Med Sci. 2020;15(3):203\u201310.","journal-title":"J Taibah Univ Med Sci"},{"key":"1518_CR26","doi-asserted-by":"crossref","unstructured":"Al-Sweih N, Jamal W, Mokaddas E, Habashy N, Kurdi A, Mohamed N. Evaluation of the in vitro activity of ceftaroline, ceftazidime\/avibactam and comparator antimicrobial agents against clinical isolates from paediatric patients in Kuwait: ATLAS data 2012\u201319. 2021.","DOI":"10.1093\/jacamr\/dlab159"},{"key":"1518_CR27","doi-asserted-by":"crossref","unstructured":"Asempa TE, Nicolau DP, Kuti JL. Carbapenem-Nonsusceptible Pseudomonas aeruginosa Isolates from Intensive Care Units in the United States: a Potential Role for New \u03b2-Lactam Combination Agents. J Clin Microbiol. 2019;57(8).","DOI":"10.1128\/JCM.00535-19"},{"key":"1518_CR28","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.2147\/IDR.S173804","volume":"11","author":"SD Atkin","year":"2018","unstructured":"Atkin SD, Abid S, Foster M, Bose M, Keller A, Hollaway R, et al. Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime-avibactam. Infect Drug Resist. 2018;11:1499\u2013510.","journal-title":"Infect Drug Resist"},{"issue":"5","key":"1518_CR29","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.ijantimicag.2018.07.011","volume":"52","author":"LM Avery","year":"2018","unstructured":"Avery LM, Nicolau DP. Assessing the in vitro activity of ceftazidime\/avibactam and aztreonam among carbapenemase-producing Enterobacteriaceae: defining the zone of hope. Int J Antimicrob Agents. 2018;52(5):688\u201391.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"1518_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2022.115652","volume":"103","author":"YD Bakthavatchalam","year":"2022","unstructured":"Bakthavatchalam YD, Routray A, Mane A, Kamat S, Gupta A, Bari AK, et al. In vitro activity of Ceftazidime-Avibactam and its comparators against Carbapenem resistant Enterobacterales collected across India: results from ATLAS surveillance 2018 to 2019. Diagn Microbiol Infect Dis. 2022;103(1): 115652.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"3","key":"1518_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2021.115327","volume":"100","author":"SS Bhagwat","year":"2021","unstructured":"Bhagwat SS, Legakis NJ, Skalidis T, Loannidis A, Goumenopoulos C, Joshi PR, et al. In vitro activity of cefepime\/zidebactam (WCK 5222) against recent Gram-negative isolates collected from high resistance settings of Greek hospitals. Diagn Microbiol Infect Dis. 2021;100(3): 115327.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1518_CR32","unstructured":"Biagi M, Wu T, Lee M, Patel S, Butler D, Wenzler E. Searching for the Optimal Treatment for Metallo-and Serine-\u03b2-Lactamase Producing Enterobacteriaceae: Aztreonam in Combination with Ceftazidime-avibactam or Meropenem-vaborbactam. Antimicrobial agents and chemotherapy. 2019:AAC. 01426\u201319."},{"key":"1518_CR33","doi-asserted-by":"crossref","unstructured":"Bianco G, Boattini M, Comini S, Leone A, Bondi A, Zaccaria T, et al. Implementation of Chromatic Super CAZ\/AVI\u00ae medium for active surveillance of ceftazidime-avibactam resistance: preventing the loop from becoming a spiral. 2022.","DOI":"10.1007\/s10096-022-04480-x"},{"issue":"5","key":"1518_CR34","doi-asserted-by":"publisher","first-page":"e00847","DOI":"10.1128\/spectrum.00847-23","volume":"11","author":"K Borde","year":"2023","unstructured":"Borde K, Kareem M, Sharma RM, Dass SM, Ravi V, Mathai D. In vitro activity of cefiderocol against comparators (ceftazidime-avibactam, ceftazidime-avibactam\/aztreonam combination, and colistin) against clinical isolates of meropenem-resistant Klebsiella pneumoniae from India. Microbiol Spect. 2023;11(5):e00847-e923.","journal-title":"Microbiol Spect"},{"issue":"1","key":"1518_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.11.009","volume":"55","author":"J Borjan","year":"2020","unstructured":"Borjan J, Meyer KA, Shields RK, Wenzler E. Activity of ceftazidime-avibactam alone and in combination with polymyxin B against carbapenem-resistant Klebsiella pneumoniae in a tandem in vitro time-kill\/in vivo Galleria mellonella survival model analysis. Int J Antimicrob Agents. 2020;55(1): 105852.","journal-title":"Int J Antimicrob Agents"},{"key":"1518_CR36","doi-asserted-by":"crossref","unstructured":"Bouxom H, Fournier D, Bouiller K, Hocquet D, Bertrand X. Which non-carbapenem antibiotics are active against extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae? 2018.","DOI":"10.1016\/j.ijantimicag.2018.03.014"},{"key":"1518_CR37","doi-asserted-by":"crossref","unstructured":"Buehrle DJ, Shields RK, Chen L, Hao B, Press EG, Alkrouk A, et al. Evaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates. 2016.","DOI":"10.1128\/AAC.02969-15"},{"issue":"9","key":"1518_CR38","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1007\/s10096-024-04896-7","volume":"43","author":"E Buyukyanbolu","year":"2024","unstructured":"Buyukyanbolu E, Genc L, Cyr EA, Karakus M, Comert F, Otlu B, et al. Antimicrobial susceptibility profile of ceftolozane\/tazobactam, ceftazidime\/avibactam and cefiderocol against carbapenem-resistant Pseudomonas aeruginosa clinical isolates from T\u00fcrkiye. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2024;43(9):1787\u201394.","journal-title":"Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol"},{"issue":"3","key":"1518_CR39","doi-asserted-by":"publisher","first-page":"228","DOI":"10.37201\/req\/019.2021","volume":"34","author":"R Cant\u00f3n","year":"2021","unstructured":"Cant\u00f3n R, Loza E, Arcay RM, Cercenado E, Castillo FJ, Cisterna R, et al. Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016\u20132018). Revista espanola de quimioterapia\u202f: publicacion oficial de la Sociedad Espanola de Quimioterapia. 2021;34(3):228\u201337.","journal-title":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia"},{"key":"1518_CR40","doi-asserted-by":"crossref","unstructured":"Carvalho TN, Kobs VC, Hille D, Deglmann RC, Melo LH, Fran\u00e7a PHC. Evaluation of in-vitro susceptibility of \u00df-lactam-resistant Gram-negative bacilli to ceftazidime-avibactam and ceftolozane-tazobactam from clinical samples of a general hospital in southern Brazil. Revista da Sociedade Brasileira de Medicina Tropical. 2023;56.","DOI":"10.1590\/0037-8682-0277-2022"},{"key":"1518_CR41","doi-asserted-by":"crossref","unstructured":"Castanheira M, Doyle TB, Deshpande LM, Mendes RE, Sader HS. Activity of ceftazidime\/avibactam, meropenem\/vaborbactam and imipenem\/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals. 2021.","DOI":"10.1016\/j.ijantimicag.2021.106439"},{"key":"1518_CR42","doi-asserted-by":"crossref","unstructured":"Castanheira M, Doyle TB, Mendes RE, Sader HS. Comparative Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Enterobacteriaceae Isolates Producing Extended-Spectrum \u03b2-Lactamases from U.S. Hospitals. Antimicrobial agents and chemotherapy. 2019;63(7).","DOI":"10.1128\/AAC.00160-19"},{"key":"1518_CR43","doi-asserted-by":"crossref","unstructured":"Castanheira M, Mendes RE, Sader HS. Low frequency of ceftazidime-avibactam resistance among Enterobacteriaceae isolates carrying blaKPC collected in U.S. hospitals from 2012 to 2015. 2017.","DOI":"10.1128\/AAC.02369-16"},{"key":"1518_CR44","doi-asserted-by":"crossref","unstructured":"Chatzidimitriou M, Chatzivasileiou P, Sakellariou G, Kyriazidi M, Kavvada A, Chatzidimitriou D, et al. Ceftazidime\/avibactam and eravacycline susceptibility of carbapenem-resistant Klebsiella pneumoniae in two Greek tertiary teaching hospitals. 2021.","DOI":"10.1556\/030.2021.01364"},{"key":"1518_CR45","doi-asserted-by":"crossref","unstructured":"Chen D, Xiao L, Hong D, Zhao Y, Hu X, Shi S, et al. Epidemiology of resistance of carbapenemase-producing Klebsiella pneumoniae to ceftazidime-avibactam in a Chinese hospital. 2022.","DOI":"10.1111\/jam.15166"},{"key":"1518_CR46","doi-asserted-by":"crossref","unstructured":"Chen T, Xu W, Yu K, Zeng W, Xu C, Cao J, et al. In Vitro Activity of Ceftazidime-Avibactam Alone and in Combination with Amikacin against Colistin-Resistant Gram-Negative Pathogens. 2021.","DOI":"10.1089\/mdr.2019.0463"},{"key":"1518_CR47","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jgar.2024.01.014","volume":"36","author":"Y Chen","year":"2024","unstructured":"Chen Y, Xiang G, Liu P, Zhou X, Guo P, Wu Z, et al. Prevalence and molecular characteristics of ceftazidime-avibactam resistance among carbapenem-resistant Pseudomonas aeruginosa clinical isolates. J Glob Antimicrob Resist. 2024;36:276\u201383.","journal-title":"J Glob Antimicrob Resist"},{"key":"1518_CR48","doi-asserted-by":"crossref","unstructured":"Danjean M, Hobson CA, Gits-Muselli M, Courroux C, Monjault A, Bonacorsi S, et al. Evaluation of the inoculum effect of new antibiotics against carbapenem-resistant enterobacterales. 2022.","DOI":"10.1016\/j.cmi.2022.06.018"},{"issue":"5","key":"1518_CR49","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1128\/AAC.03042-15","volume":"60","author":"BL de Jonge","year":"2016","unstructured":"de Jonge BL, Karlowsky JA, Kazmierczak KM, Biedenbach DJ, Sahm DF, Nichols WW. In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014). Antimicrob Agents Chemother. 2016;60(5):3163\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"1518_CR50","doi-asserted-by":"crossref","unstructured":"Esposito S, Stone GG, Papaparaskevas J. In vitro activity of aztreonam\/avibactam against a global collection of Klebsiella pneumoniae collected from defined culture sources in 2016 and 2017. 2021.","DOI":"10.1016\/j.jgar.2020.08.004"},{"key":"1518_CR51","unstructured":"Fraile-Ribot PA, Zamorano L, Orellana R, Del Barrio-Tofi\u00f1o E, S\u00e1nchez-Diener I, Cortes-Lara S, et al. Activity of imipenem-relebactam against a large collection of pseudomonas aeruginosa clinical isolates and isogenic \u03b2-lactam-resistant mutants. 2020."},{"key":"1518_CR52","first-page":"1","volume":"65","author":"P Gaibani","year":"2017","unstructured":"Gaibani P, Lewis RE, Volpe SL, Giannella M, Campoli C, Landini MP, et al. In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2017;65:1\u20133.","journal-title":"Int J Infect Dis IJID Off Publ Int Soc Infect Dis"},{"key":"1518_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jgar.2021.07.014","volume":"27","author":"V Gant","year":"2021","unstructured":"Gant V, Hussain A, Bain M, Longshaw C, Henriksen AS. In vitro activity of cefiderocol and comparators against Gram-negative bacterial isolates from a series of surveillance studies in England: 2014\u20132018. J Glob Antimicrob Resist. 2021;27:1\u201311.","journal-title":"J Glob Antimicrob Resist"},{"key":"1518_CR54","doi-asserted-by":"crossref","unstructured":"Giani T, Antonelli A, Sennati S, Di Pilato V, Chiarelli A, Cannatelli A, et al. Results of the Italian infection-Carbapenem Resistance Evaluation Surveillance Trial (iCREST-IT): Activity of ceftazidime\/avibactam against Enterobacterales isolated from urine. 2020.","DOI":"10.1093\/jac\/dkz547"},{"issue":"12","key":"1518_CR55","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1007\/s10096-021-04308-0","volume":"40","author":"CM Gill","year":"2021","unstructured":"Gill CM, Akta\u00fe E, Alfouzan W, Bourassa L, Brink A, Burnham CD, et al. The ERACE-PA global surveillance program: ceftolozane\/tazobactam and ceftazidime\/avibactam in vitro activity against a global collection of carbapenem-resistant pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2021;40(12):2533\u201341.","journal-title":"Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol"},{"key":"1518_CR56","doi-asserted-by":"crossref","unstructured":"Gonzalez MD, McMullen AR, Wallace MA, Crotty MP, Ritchie DJ, Burnham CAD. Susceptibility of ceftolozane-tazobactam and ceftazidime-avibactam against a collection of \u03b2-lactam-resistant gram-negative bacteria. 2017.","DOI":"10.3343\/alm.2017.37.2.174"},{"key":"1518_CR57","doi-asserted-by":"crossref","unstructured":"Grupper M, Sutherland C, Nicolau DP. Multicenter evaluation of ceftazidime-avibactam and ceftolozane-tazobactam inhibitory activity against meropenem-nonsusceptible Pseudomonas aeruginosa from blood, respiratory tract, and wounds. 2017.","DOI":"10.1128\/AAC.00875-17"},{"key":"1518_CR58","doi-asserted-by":"crossref","unstructured":"Hachem R, Reitzel R, Rolston K, Chaftari AM, Raad I. Antimicrobial activities of ceftazidime-avibactam and comparator agents against clinical bacteria isolated from patients with cancer. 2017.","DOI":"10.1128\/AAC.02106-16"},{"key":"1518_CR59","doi-asserted-by":"crossref","unstructured":"Han R, Shi Q, Wu S, Yin D, Peng M, Dong D, et al. Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) Among Carbapenem-Resistant Enterobacteriaceae Isolated From Adult and Children Patients in China. 2020.","DOI":"10.3389\/fcimb.2020.00314"},{"key":"1518_CR60","doi-asserted-by":"crossref","unstructured":"Hao M, Shi X, Lv J, Niu S, Cheng S, Du H, et al. In vitro Activity of Apramycin Against Carbapenem-Resistant and Hypervirulent Klebsiella pneumoniae Isolates. 2020.","DOI":"10.3389\/fmicb.2020.00425"},{"key":"1518_CR61","doi-asserted-by":"crossref","unstructured":"Hirsch EB, Brigman HV, Zucchi PC, Chen A, Anderson JC, Eliopoulos GM, et al. Ceftolozane-tazobactam and ceftazidime-avibactam activity against \u03b2-lactam-resistant Pseudomonas aeruginosa and extended-spectrum \u03b2-lactamase-producing Enterobacterales clinical isolates from U.S. medical centres. 2020.","DOI":"10.1016\/j.jgar.2020.04.017"},{"key":"1518_CR62","doi-asserted-by":"crossref","unstructured":"Hsueh SC, Lee YJ, Huang YT, Liao CH, Tsuji M, Hsueh PR. In vitro activities of cefiderocol, ceftolozane\/tazobactam, ceftazidime\/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan. 2019.","DOI":"10.1093\/jac\/dky425"},{"key":"1518_CR63","doi-asserted-by":"crossref","unstructured":"Hu Y, Chen J, Huang L, Liu C, Zhou H, Zhang R. Antimicrobial susceptibility study and molecular epidemiology of ceftazidime\/avibactam against Pseudomonas aeruginosa collected from clinical patients in PR China (2004\u20132021). Journal of medical microbiology. 2023;72(2).","DOI":"10.1099\/jmm.0.001656"},{"key":"1518_CR64","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00692-21","author":"Y Huang","year":"2021","unstructured":"Huang Y, Sokolowski K, Rana A, Singh N, Wang J, Chen K, et al. Generating genotype-specific aminoglycoside combinations with ceftazidime\/avibactam for KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2021. https:\/\/doi.org\/10.1128\/aac.00692-21.","journal-title":"Antimicrob Agents Chemother"},{"key":"1518_CR65","doi-asserted-by":"crossref","unstructured":"Humphries RM, Hindler JA, Wong-Beringer A, Miller SA. Activity of ceftolozane-tazobactam and ceftazidime-avibactam against beta-lactam-resistant Pseudomonas aeruginosa isolates. 2017.","DOI":"10.1128\/AAC.01858-17"},{"issue":"9","key":"1518_CR66","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1093\/jac\/dkz228","volume":"74","author":"T Idowu","year":"2019","unstructured":"Idowu T, Ammeter D, Arthur G, Zhanel GG, Schweizer F. Potentiation of \u03b2-lactam antibiotics and \u03b2-lactam\/\u03b2-lactamase inhibitor combinations against MDR and XDR Pseudomonas aeruginosa using non-ribosomal tobramycin\u2013cyclam conjugates. J Antimicrob Chemother. 2019;74(9):2640\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"1518_CR67","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.2147\/IDR.S175679","volume":"11","author":"SS Jean","year":"2018","unstructured":"Jean SS, Lu MC, Shi ZY, Tseng SH, Wu TS, Lu PL, et al. In vitro activity of ceftazidime-avibactam, ceftolozane-tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART). Infect Drug Resist. 2018;11:1983\u201392.","journal-title":"Infect Drug Resist"},{"key":"1518_CR68","doi-asserted-by":"crossref","unstructured":"Jia P, Zhu Y, Zhang H, Cheng B, Guo P, Xu Y, et al. In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program. 2022.","DOI":"10.1186\/s12866-022-02644-5"},{"key":"1518_CR69","doi-asserted-by":"crossref","unstructured":"Johnston BD, Thuras PD, Johnson JR. Activity of ceftazidime-avibactam against Escherichia coli isolates from U.S. veterans (2011) in relation to co-resistance and sequence type 131 (ST131) H30 and H30Rx status. 2020.","DOI":"10.1016\/j.diagmicrobio.2020.115034"},{"issue":"6","key":"1518_CR70","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00344-24","volume":"12","author":"MS Kang","year":"2024","unstructured":"Kang MS, Baek JY, Ko JH, Cho SY, Lee KY, Lee YH, et al. Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam. Microbiol Spect. 2024;12(6): e0034424.","journal-title":"Microbiol Spect"},{"key":"1518_CR71","doi-asserted-by":"crossref","unstructured":"Karlowsky JA, Bouchillon SK, El Mahdy Kotb R, Mohamed N, Stone GG, Sahm DF. Carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa causing infection in Africa and the Middle East: A surveillance study from the ATLAS programme (2018\u201320). 2022.","DOI":"10.1093\/jacamr\/dlac060"},{"key":"1518_CR72","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jgar.2024.05.009","volume":"38","author":"S Kayama","year":"2024","unstructured":"Kayama S, Kawakami S, Kondo K, Kitamura N, Yu L, Hayashi W, et al. In vitro activity of cefiderocol against carbapenemase-producing and meropenem-non-susceptible Gram-negative bacteria collected in the Japan Antimicrobial Resistant Bacterial Surveillance. J Glob Antimicrob Resist. 2024;38:12\u201320.","journal-title":"J Glob Antimicrob Resist"},{"key":"1518_CR73","doi-asserted-by":"crossref","unstructured":"Kettani AE, Zoukal S, Zerouali K, Hassoune S, Soussi-Abdallaoui M. In Vitro Activity of Ceftazidime-Avibactam Against Enterobacteriaceae and P. aeruginosa Isolated at the Ibn Rochd University Hospital of Casablanca. Clinical laboratory. 2023;69(10).","DOI":"10.7754\/Clin.Lab.2023.230401"},{"key":"1518_CR74","doi-asserted-by":"crossref","unstructured":"Kiratisin P, Kazmierczak K, Stone GG. In vitro activity of ceftazidime\/avibactam and comparators against carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa isolates collected globally between 2016 and 2018. 2021.","DOI":"10.1016\/j.jgar.2021.08.010"},{"key":"1518_CR75","doi-asserted-by":"crossref","unstructured":"Ko WC, Stone GG. In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015\u20132017). 2020.","DOI":"10.1186\/s12941-020-00355-1"},{"key":"1518_CR76","doi-asserted-by":"crossref","unstructured":"Kresken M, Korte-Berwanger M, Pfennigwerth N, Gatermann SG, Working Party 'Antimicrobial Resistance' of the Paul-Ehrlich-Society for C. In vitro activity of ceftazidime\/avibactam against ceftazidime-resistant Enterobacterales and Pseudomonas aeruginosa from hospitalised patients in Germany. 2021.","DOI":"10.1016\/j.jgar.2021.04.010"},{"issue":"1","key":"1518_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2021.115420","volume":"101","author":"K Krist\u00f3f","year":"2021","unstructured":"Krist\u00f3f K, Ad\u00e1mkov\u00e1 V, Adler A, Gospodarek-Komkowska E, Rafila A, Billov\u00e1 S, et al. In vitro activity of ceftazidime-avibactam and comparators against Enterobacterales and Pseudomonas aeruginosa isolates from Central Europe and Israel, 2014\u20132017 and 2018. Diagn Microbiol Infect Dis. 2021;101(1): 115420.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1518_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmmb.2024.100603","volume":"49","author":"VM Krithika","year":"2024","unstructured":"Krithika VM, Ganesan V, Rajendran T. Ceftazidime-Avibactam resistance in clinical isolates of carbapenem-resistant Klebsiella pneumoniae: a phenotypic and genotypic analysis. Indian J Med Microbiol. 2024;49: 100603.","journal-title":"Indian J Med Microbiol"},{"key":"1518_CR79","doi-asserted-by":"crossref","unstructured":"Kuo SC, Wang YC, Tan MC, Huang WC, Shiau YR, Wang HY, et al. In vitro activity of imipenem\/relebactam, meropenem\/vaborbactam, ceftazidime\/avibactam, cefepime\/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan. 2021.","DOI":"10.1093\/jac\/dkab141"},{"key":"1518_CR80","doi-asserted-by":"crossref","unstructured":"Lasko MJ, Huse HK, Nicolau DP, Kuti JL. Contemporary analysis of ETEST for antibiotic susceptibility and minimum inhibitory concentration agreement against Pseudomonas aeruginosa from patients with cystic fibrosis. 2021.","DOI":"10.1186\/s12941-021-00415-0"},{"issue":"1","key":"1518_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2020.115227","volume":"99","author":"M Lee","year":"2021","unstructured":"Lee M, Abbey T, Biagi M, Wenzler E. Activity of aztreonam in combination with ceftazidime\u2013avibactam against serine-and metallo-\u03b2-lactamase\u2013producing Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 2021;99(1): 115227.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1518_CR82","doi-asserted-by":"crossref","unstructured":"Lee YL, Ko WC, Lee WS, Lu PL, Chen YH, Cheng SH, et al. In-vitro activity of cefiderocol, cefepime\/zidebactam, cefepime\/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017\u20132020. 2021.","DOI":"10.1016\/j.ijantimicag.2021.106377"},{"key":"1518_CR83","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jgar.2022.02.018","volume":"29","author":"EV Lemos-Luengas","year":"2022","unstructured":"Lemos-Luengas EV, Renter\u00eda-Valoyes S, C\u00e1rdenas-Isaza P, Ramos-Castaneda JA. In vitro activity of ceftazidime\/avibactam against Gram-negative strains in Colombia 2014\u20132018. J Glob Antimicrob Resist. 2022;29:141\u20136.","journal-title":"J Glob Antimicrob Resist"},{"issue":"6","key":"1518_CR84","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02806-23","volume":"11","author":"D Li","year":"2023","unstructured":"Li D, Yu H, Huang X, Long S, Zhang J. In vitro activity of ceftazidime-avibactam, imipenem-relebactam, aztreonam-avibactam, and comparators toward carbapenem-resistant and hypervirulent Klebsiella pneumoniae isolates. Microbiol Spect. 2023;11(6): e0280623.","journal-title":"Microbiol Spect"},{"key":"1518_CR85","doi-asserted-by":"crossref","unstructured":"Li H, Oliver A, Shields RK, Kamat S, Stone G, Estabrook M. Molecular characterization of clinically isolated Pseudomonas aeruginosa with varying resistance to ceftazidime-avibactam and ceftolozane-tazobactam collected as a part of the ATLAS global surveillance program from 2020 to 2021. Antimicrob Agents Chemother. 2024:e0067024.","DOI":"10.1128\/aac.00670-24"},{"issue":"1","key":"1518_CR86","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12941-024-00674-7","volume":"23","author":"J Li","year":"2024","unstructured":"Li J, Tang M, Liu Z, Wei Y, Xia F, Xia Y, et al. Molecular characterization of extensively drug-resistant hypervirulent Pseudomonas aeruginosa isolates in China. Ann Clin Microbiol Antimicrob. 2024;23(1):13.","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"1","key":"1518_CR87","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13756-023-01331-y","volume":"12","author":"L Li","year":"2023","unstructured":"Li L, Li S, Wei X, Lu Z, Qin X, Li M. Infection with Carbapenem-resistant Hypervirulent Klebsiella Pneumoniae: clinical, virulence and molecular epidemiological characteristics. Antimicrob Resist Infect Control. 2023;12(1):124.","journal-title":"Antimicrob Resist Infect Control"},{"key":"1518_CR88","doi-asserted-by":"crossref","unstructured":"Liao CH, Lee NY, Tang HJ, Lee SSJ, Lin CF, Lu PL, et al. Antimicrobial activities of ceftazidime-avibactam, ceftolozane-tazobactam, and other agents against escherichia coli, klebsiella pneumoniae, and pseudomonas aeruginosa isolated from intensive care units in Taiwan: Results from the surveillance of multicenter antimicrobial resistance in Taiwan in 2016. 2019.","DOI":"10.2147\/IDR.S193638"},{"key":"1518_CR89","doi-asserted-by":"crossref","unstructured":"Lim TP, Ho JY, Teo JQ, Sim JH, Tan SH, Tan TT, et al. In Vitro Susceptibility to Ceftazidime-Avibactam and Comparator Antimicrobial Agents of Carbapenem-Resistant Enterobacterales Isolates. Microorganisms. 2023;11(9).","DOI":"10.3390\/microorganisms11092158"},{"key":"1518_CR90","doi-asserted-by":"crossref","unstructured":"Liu PY, Ko WC, Lee WS, Lu PL, Chen YH, Cheng SH, et al. In\u00a0vitro activity of cefiderocol, cefepime\/enmetazobactam, cefepime\/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018\u20132020. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. 2022;55(5):888\u201395.","DOI":"10.1016\/j.jmii.2021.08.012"},{"key":"1518_CR91","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.3389\/fmicb.2019.02029","volume":"10","author":"X Ma","year":"2019","unstructured":"Ma X, He Y, Yu X, Cai Y, Zeng J, Cai R, et al. Ceftazidime\/avibactam improves the antibacterial efficacy of polymyxin B against polymyxin B heteroresistant KPC-2-producing Klebsiella pneumoniae and hinders emergence of resistant subpopulation in vitro. Front Microbiol. 2019;10:2029.","journal-title":"Front Microbiol"},{"issue":"1","key":"1518_CR92","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1089\/mdr.2016.0293","volume":"24","author":"N Manning","year":"2018","unstructured":"Manning N, Balabanian G, Rose M, Landman D, Quale J. Activity of ceftazidime\u2013avibactam against clinical isolates of Klebsiella pneumoniae, including KPC-carrying isolates, endemic to New York City. Microb Drug Resist. 2018;24(1):35\u20139.","journal-title":"Microb Drug Resist"},{"key":"1518_CR93","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1007\/s10096-021-04197-3","volume":"40","author":"S Maraki","year":"2021","unstructured":"Maraki S, Mavromanolaki VE, Moraitis P, Stafylaki D, Kasimati A, Magkafouraki E, et al. Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-\u03b2-lactamase-producing Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis. 2021;40:1755\u20139.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"1518_CR94","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.04437-22","volume":"11","author":"M Marner","year":"2023","unstructured":"Marner M, Kolberg L, Horst J, B\u00f6hringer N, H\u00fcbner J, Kresna IDM, et al. Antimicrobial activity of ceftazidime-avibactam, ceftolozane-tazobactam, cefiderocol, and novel darobactin analogs against multidrug-resistant pseudomonas aeruginosa isolates from pediatric and adolescent cystic fibrosis patients. Microbiol Spect. 2023;11(1): e0443722.","journal-title":"Microbiol Spect"},{"key":"1518_CR95","doi-asserted-by":"crossref","unstructured":"Mataraci Kara E, Yilmaz M, Istanbullu Tosun A, \u00d6zbek \u00c7elik B. Evaluation of the synergy of ceftazidime\/avibactam in combination with colistin, doripenem, levofloxacin, tigecycline, and tobramycin against OXA-48 producing Enterobacterales. 2020.","DOI":"10.1080\/1120009X.2020.1761172"},{"key":"1518_CR96","doi-asserted-by":"crossref","unstructured":"Matarac\u0131 Kara E, Y\u0131lmaz M, \u00d6zbek \u00c7elik B. In vitro activities of ceftazidime\/avibactam alone or in combination with antibiotics against multidrug-resistant Acinetobacter baumannii isolates. 2019.","DOI":"10.1016\/j.jgar.2018.12.004"},{"key":"1518_CR97","doi-asserted-by":"crossref","unstructured":"Mendes RE, Rhomberg PR, Watters AA, Castanheira M. In vitro activity of the orally bioavailable ceftibuten\/VNRX-7145 (VNRX-5236 etzadroxil) combination against a challenge set of Enterobacterales pathogens carrying molecularly characterized \u03b2-lactamase genes. 2022.","DOI":"10.1093\/jac\/dkab425"},{"key":"1518_CR98","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00779-19","author":"S Mikhail","year":"2019","unstructured":"Mikhail S, Singh NB, Kebriaei R, Rice SA, Stamper KC, Castanheira M, et al. Evaluation of the synergy of ceftazidime-avibactam in combination with meropenem, amikacin, aztreonam, colistin, or fosfomycin against well-characterized multidrug-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2019. https:\/\/doi.org\/10.1128\/aac.00779-19.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1518_CR99","doi-asserted-by":"publisher","first-page":"e0065122","DOI":"10.1128\/msphere.00651-22","volume":"8","author":"MF Mojica","year":"2023","unstructured":"Mojica MF, De La Cadena E, Garc\u00eda-Betancur JC, Porras J, Novoa-Caicedo I, P\u00e1ez-Zamora L, et al. Molecular mechanisms of resistance to ceftazidime\/avibactam in clinical isolates of enterobacterales and pseudomonas aeruginosa in latin american hospitals. mSphere. 2023;8(2):e0065122.","journal-title":"mSphere."},{"key":"1518_CR100","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00585-21","author":"MM Montero","year":"2021","unstructured":"Montero MM, Domene Ochoa S, L\u00f3pez-Causap\u00e9 C, Luque S, Sorl\u00ed L, Campillo N, et al. Time-kill evaluation of antibiotic combinations containing ceftazidime-avibactam against extensively drug-resistant Pseudomonas aeruginosa and their potential role against ceftazidime-avibactam-resistant isolates. Microbiol Spect. 2021. https:\/\/doi.org\/10.1128\/spectrum.00585-21.","journal-title":"Microbiol Spect"},{"issue":"3","key":"1518_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.107081","volume":"63","author":"S Mushtaq","year":"2024","unstructured":"Mushtaq S, Vickers A, Woodford N, Livermore DM. Activity of aztreonam\/avibactam and ceftazidime\/avibactam against Enterobacterales with carbapenemase-independent carbapenem resistance. Int J Antimicrob Agents. 2024;63(3): 107081.","journal-title":"Int J Antimicrob Agents"},{"key":"1518_CR102","doi-asserted-by":"crossref","unstructured":"Nardulli P, Hall GG, Quarta A, Fruscio G, Laforgia M, Garrisi VM, et al. Antibiotic Abuse and Antimicrobial Resistance in Hospital Environment: A Retrospective Observational Comparative Study. 2022.","DOI":"10.3390\/medicina58091257"},{"key":"1518_CR103","doi-asserted-by":"crossref","unstructured":"Nasomsong W, Nulsopapon P, Changpradub D, Pongchaidecha M, Pungcharoenkijkul S, Juntanawiwat P, et al. The potential use of ceftazidime-avibactam against carbapenem resistant klebsiella pneumoniae clinical isolates harboring different carbapenemase types in a thai university hospital. 2021.","DOI":"10.2147\/DDDT.S321147"},{"issue":"2","key":"1518_CR104","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/jac\/dkx419","volume":"73","author":"S Nath","year":"2018","unstructured":"Nath S, Moussavi F, Abraham D, Landman D, Quale J. In vitro and in vivo activity of single and dual antimicrobial agents against KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2018;73(2):431\u20136.","journal-title":"J Antimicrob Chemother"},{"key":"1518_CR105","doi-asserted-by":"crossref","unstructured":"O\u2019Neall D, Juhasz E, Toth A, Urban E, Szabo J, Melegh S, et al. Ceftazidime\u2013avibactam and ceftolozane\u2013tazobactam susceptibility of multidrug resistant Pseudomonas aeruginosa strains in Hungary. 2020.","DOI":"10.1556\/030.2020.01152"},{"issue":"9","key":"1518_CR106","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1089\/mdr.2018.0234","volume":"25","author":"D Ojdana","year":"2019","unstructured":"Ojdana D, Gutowska A, Sacha P, Majewski P, Wieczorek P, Tryniszewska E. Activity of ceftazidime-avibactam alone and in combination with ertapenem, fosfomycin, and tigecycline against carbapenemase-producing Klebsiella pneumoniae. Microb Drug Resist. 2019;25(9):1357\u201364.","journal-title":"Microb Drug Resist"},{"key":"1518_CR107","doi-asserted-by":"crossref","unstructured":"Okoliegbe IN, Hijazi K, Cooper K, Ironside C, Gould IM. Trends of antimicrobial resistance and combination susceptibility testing of multidrug-resistant pseudomonas aeruginosa isolates from cystic fibrosis patients: a 10-year update. 2021.","DOI":"10.1128\/AAC.02483-20"},{"key":"1518_CR108","doi-asserted-by":"crossref","unstructured":"Olalekan A, Onwugamba F, Iwalokun B, Mellmann A, Becker K, Schaumburg F. High proportion of carbapenemase-producing Escherichia coli and Klebsiella pneumoniae among extended-spectrum \u03b2-lactamase-producers in Nigerian hospitals. 2020.","DOI":"10.1016\/j.jgar.2019.09.007"},{"key":"1518_CR109","doi-asserted-by":"crossref","unstructured":"Palombo M, Secci B, Bovo F, Gatti M, Ambretti S, Gaibani P. In Vitro Evaluation of Increasing Avibactam Concentrations on Ceftazidime Activity against Ceftazidime\/Avibactam-Susceptible and Resistant KPC-Producing Klebsiella pneumoniae Clinical Isolates. Antibiotics (Basel, Switzerland). 2023;12(12).","DOI":"10.3390\/antibiotics12121707"},{"key":"1518_CR110","doi-asserted-by":"crossref","unstructured":"P\u00e9rez A, Gato E, P\u00e9rez-Llarena J, Fern\u00e1ndez-Cuenca F, Gude MJ, Ovia\u00f1o M, et al. High incidence of MDR and XDR Pseudomonas aeruginosa isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial. 2019.","DOI":"10.1093\/jac\/dkz030"},{"issue":"1","key":"1518_CR111","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1186\/s12879-021-06153-0","volume":"21","author":"D Pi\u00e9rard","year":"2021","unstructured":"Pi\u00e9rard D, Stone GG. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016\u20132018). BMC Infect Dis. 2021;21(1):600.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"1518_CR112","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4103\/ijmm.IJMM_19_189","volume":"37","author":"AK Pragasam","year":"2019","unstructured":"Pragasam AK, Veeraraghavan B, Shankar BA, Bakthavatchalam YD, Mathuram A, George B, et al. Will ceftazidime\/avibactam plus aztreonam be effective for NDM and OXA-48-Like producing organisms: Lessons learnt from In vitro study. Indian J Med Microbiol. 2019;37(1):34\u201341.","journal-title":"Indian J Med Microbiol"},{"key":"1518_CR113","doi-asserted-by":"crossref","unstructured":"Ramadan RA, Bedawy AM, Negm EM, Hassan TH, Ibrahim DA, Elsheikh SM, et al. Carbapenem-Resistant Klebsiella pneumoniae Among Patients with Ventilator-Associated Pneumonia: Evaluation of Antibiotic Combinations and Susceptibility to New Antibiotics. 2022.","DOI":"10.2147\/IDR.S371248"},{"key":"1518_CR114","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jgar.2019.07.003","volume":"19","author":"E Ramalheira","year":"2019","unstructured":"Ramalheira E, Stone GG. Longitudinal analysis of the in vitro activity of ceftazidime\/avibactam versus Enterobacteriaceae, 2012\u20132016. J Glob Antimicrob Resist. 2019;19:106\u201315.","journal-title":"J Glob Antimicrob Resist"},{"issue":"3","key":"1518_CR115","first-page":"136","volume":"43","author":"F Romanelli","year":"2020","unstructured":"Romanelli F, De Robertis A, Carone G, Dalfino L, Stufano M, Del Prete R, et al. In vitro activity of ceftazidime\/avibactam alone and in combination with fosfomycin and carbapenems against KPC-producing Klebsiella pneumoniae. New Microbiol. 2020;43(3):136\u20138.","journal-title":"New Microbiol"},{"key":"1518_CR116","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jgar.2023.08.010","volume":"35","author":"P-E Romina","year":"2023","unstructured":"Romina P-E, Luc\u00eda A, Leticia C, Federica F, Pablo \u00c1, Ver\u00f3nica S, et al. In vitro effectiveness of ceftazidime-avibactam in combination with aztreonam on carbapenemase-producing Enterobacterales. J Glob Antimicrob Resist. 2023;35:62\u20136.","journal-title":"J Glob Antimicrob Resist"},{"issue":"3","key":"1518_CR117","doi-asserted-by":"publisher","first-page":"106111","DOI":"10.1016\/j.ijantimicag.2020.106111","volume":"56","author":"GM Rossolini","year":"2020","unstructured":"Rossolini GM, Stone GG. Assessment of the in vitro activity of ceftazidime\/avibactam against a global collection of multidrug-resistant Klebsiella spp. from the INFORM surveillance programme (2015\u20132017). Int J Antimicrob Agents. 2020;56(3):106111.","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"1518_CR118","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s10096-023-04562-4","volume":"42","author":"HS Sader","year":"2023","unstructured":"Sader HS, Carvalhaes CG, Huband MD, Mendes RE, Castanheira M. Antimicrobial activity of ceftibuten-avibactam against a global collection of Enterobacterales from patients with urinary tract infections (2021). Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2023;42(4):453\u20139.","journal-title":"Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol"},{"key":"1518_CR119","doi-asserted-by":"crossref","unstructured":"Sader HS, Carvalhaes CG, Streit JM, Doyle TB, Castanheira M. Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested against Pseudomonas aeruginosa and Klebsiella pneumoniae Isolates from United States Medical Centers in 2016\u20132018. 2021.","DOI":"10.1089\/mdr.2020.0217"},{"key":"1518_CR120","doi-asserted-by":"crossref","unstructured":"Sader HS, Castanheira M, Duncan LR, Flamm RK. Antimicrobial Susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015\u20132016. 2018.","DOI":"10.1016\/j.diagmicrobio.2018.04.012"},{"key":"1518_CR121","doi-asserted-by":"crossref","unstructured":"Sader HS, Castanheira M, Farrell DJ, Flamm RK, Jones RN. Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011\u20132014). 2015.","DOI":"10.1016\/j.diagmicrobio.2015.06.008"},{"key":"1518_CR122","doi-asserted-by":"crossref","unstructured":"Sader HS, Castanheira M, Flamm RK, Huband MD, Jones RN. Ceftazidime-Avibactam Activity against Aerobic Gram Negative Organisms Isolated from Intra-Abdominal Infections in United States Hospitals, 2012\u20132014. 2016.","DOI":"10.1089\/sur.2016.036"},{"issue":"3","key":"1518_CR123","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.diagmicrobio.2016.11.019","volume":"87","author":"HS Sader","year":"2017","unstructured":"Sader HS, Castanheira M, Jones RN, Flamm RK. Antimicrobial activity of ceftazidime-avibactam and comparator agents when tested against bacterial isolates causing infection in cancer patients (2013\u20132014). Diagn Microbiol Infect Dis. 2017;87(3):261\u20135.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"11","key":"1518_CR124","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1093\/jac\/dky279","volume":"73","author":"HS Sader","year":"2018","unstructured":"Sader HS, Castanheira M, Mendes RE, Flamm RK. Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015\u201317). J Antimicrob Chemother. 2018;73(11):3053\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"1518_CR125","doi-asserted-by":"crossref","unstructured":"Sader HS, Castanheira M, Mendes RE, Flamm RK, Farrell DJ, Jones RN. Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. Medical Centers in 2012 and 2013. 2015.","DOI":"10.1128\/AAC.05024-14"},{"issue":"3","key":"1518_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2019.06.002","volume":"95","author":"HS Sader","year":"2019","unstructured":"Sader HS, Castanheira M, Streit JM, Flamm RK. Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bloodstream infections in United States medical centers (2015\u20132017). Diagn Microbiol Infect Dis. 2019;95(3): 114850.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1518_CR127","doi-asserted-by":"crossref","unstructured":"Sader HS, Duncan LR, Doyle TB, Castanheira M. Antimicrobial activity of ceftazidime\/avibactam, ceftolozane\/tazobactam and comparator agents against Pseudomonas aeruginosa from cystic fibrosis patients. 2021.","DOI":"10.1093\/jacamr\/dlab126"},{"issue":"3","key":"1518_CR128","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2019.05.005","volume":"96","author":"HS Sader","year":"2020","unstructured":"Sader HS, Flamm RK, Carvalhaes CG, Castanheira M. Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017\u20132018). Diagn Microbiol Infect Dis. 2020;96(3): 114833.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"2","key":"1518_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2023.115945","volume":"106","author":"HS Sader","year":"2023","unstructured":"Sader HS, Mendes RE, Duncan L, Kimbrough JH, Carvalhaes CG, Castanheira M. Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug-resistant Enterobacterales from United States Medical Centers (2018\u20132022). Diagn Microbiol Infect Dis. 2023;106(2): 115945.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1518_CR130","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01018-18","author":"RK Shields","year":"2018","unstructured":"Shields RK, Nguyen MH, Hao B, Kline EG, Clancy CJ. Colistin does not potentiate ceftazidime-avibactam killing of carbapenem-resistant Enterobacteriaceae in vitro or suppress emergence of ceftazidime-avibactam resistance. Antimicrob Agents Chemother. 2018. https:\/\/doi.org\/10.1128\/aac.01018-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"1518_CR131","doi-asserted-by":"crossref","unstructured":"Sophonsri A, Kalu M, Wong-Beringer A. Comparative In Vitro Activity of Ceftazidime-Avibactam, Imipenem-Relebactam, and Meropenem-Vaborbactam against Carbapenem-Resistant Clinical Isolates of Klebsiella pneumoniae and Pseudomonas aeruginosa. Antibiotics (Basel, Switzerland). 2024;13(5).","DOI":"10.3390\/antibiotics13050416"},{"issue":"3","key":"1518_CR132","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40121-023-00762-9","volume":"12","author":"A Soriano","year":"2023","unstructured":"Soriano A, Montravers P, Bassetti M, Klyasova G, Daikos G, Irani P, et al. The use and effectiveness of ceftazidime-avibactam in real-world clinical practice: EZTEAM study. Infect Dis Ther. 2023;12(3):891\u2013917.","journal-title":"Infect Dis Ther"},{"key":"1518_CR133","doi-asserted-by":"crossref","unstructured":"Spiliopoulou I, Kazmierczak K, Stone GG. In vitro activity of ceftazidime\/avibactam against isolates of carbapenem-non-susceptible Enterobacteriaceae collected during the INFORM global surveillance programme (2015\u201317). 2020.","DOI":"10.1093\/jac\/dkz456"},{"issue":"3","key":"1518_CR134","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01473-23","volume":"12","author":"G Stone","year":"2024","unstructured":"Stone G, Wise M, Utt E. In vitro activity of ceftazidime-avibactam and comparators against OXA-48-like Enterobacterales collected between 2016 and 2020. Microbiol Spect. 2024;12(3): e0147323.","journal-title":"Microbiol Spect"},{"issue":"1","key":"1518_CR135","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12941-022-00504-8","volume":"21","author":"GG Stone","year":"2022","unstructured":"Stone GG, Hackel MA. Antimicrobial activity of ceftazidime-avibactam and comparators against levofloxacin-resistant Escherichia coli collected from four geographic regions, 2012\u20132018. Ann Clin Microbiol Antimicrob. 2022;21(1):13.","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"1518_CR136","doi-asserted-by":"crossref","unstructured":"Stone GG, Ponce-De-Leon A. In vitro activity of ceftazidime\/avibactam and comparators against Gram-negative bacterial isolates collected from Latin American centres between 2015 and 2017. 2020.","DOI":"10.1093\/jac\/dkaa089"},{"issue":"1","key":"1518_CR137","doi-asserted-by":"publisher","first-page":"114835","DOI":"10.1016\/j.diagmicrobio.2019.05.007","volume":"96","author":"GG Stone","year":"2020","unstructured":"Stone GG, Smayevsky J, Kazmierczak K. Longitudinal analysis of the in vitro activity of ceftazidime-avibactam vs. Pseudomonas aeruginosa, 2012\u20132016. Diagn Microbiol Infect Dis. 2020;96(1):114835.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1518_CR138","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jgar.2023.09.004","volume":"35","author":"LC Torres-Castillo","year":"2023","unstructured":"Torres-Castillo LC, Fandi\u00f1o C, Ramos MP, Ramos-Castaneda JA, Rioseco ML, Juliet C. In vitro activity of ceftazidime-avibactam against Gram-negative strains in Chile 2015\u20132021. J Glob Antimicrob Resist. 2023;35:143\u20138.","journal-title":"J Glob Antimicrob Resist"},{"key":"1518_CR139","doi-asserted-by":"crossref","unstructured":"V\u00e1zquez-Ucha JC, Seoane-Est\u00e9vez A, Rodi\u00f1o-Janeiro BK, Gonz\u00e1lez-Bardanca M, Conde-P\u00e9rez K, Mart\u00ednez-Guiti\u00e1n M, et al. Activity of imipenem\/relebactam against a Spanish nationwide collection of carbapenemase-producing Enterobacterales. 2021.","DOI":"10.1093\/jac\/dkab043"},{"key":"1518_CR140","doi-asserted-by":"crossref","unstructured":"Viala B, Zaidi FZ, Bastide M, Dumont Y, Le Moing V, Jean-Pierre H, et al. Assessment of the in Vitro Activities of Ceftolozane\/Tazobactam and Ceftazidime\/Avibactam in a Collection of Beta-Lactam-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Clinical Isolates at Montpellier University Hospital, France. 2019.","DOI":"10.1089\/mdr.2018.0439"},{"issue":"3","key":"1518_CR141","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00932-23","volume":"11","author":"L Wang","year":"2023","unstructured":"Wang L, Zhang X, Zhou X, Yang F, Guo Q, Wang M. Comparison of in vitro activity of ceftazidime-avibactam and imipenem-relebactam against clinical isolates of pseudomonas aeruginosa. Microbiol Spect. 2023;11(3): e0093223.","journal-title":"Microbiol Spect"},{"key":"1518_CR142","doi-asserted-by":"crossref","unstructured":"Weber C, Schultze T, G\u00f6ttig S, Kessel J, Schr\u00f6der A, Tietgen M, et al. Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital. 2022.","DOI":"10.1128\/spectrum.01697-22"},{"key":"1518_CR143","doi-asserted-by":"publisher","first-page":"6061","DOI":"10.2147\/IDR.S420898","volume":"16","author":"L Wen","year":"2023","unstructured":"Wen L, Luo C, Chen X, Liu T, Li X, Wang M. In vitro activity of cefepime\/avibactam against carbapenem resistant klebsiella pneumoniae and integrative metabolomics-proteomics approach for resistance mechanism: a single-center study. Infect Drug Resist. 2023;16:6061\u201377.","journal-title":"Infect Drug Resist"},{"key":"1518_CR144","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jgar.2023.08.022","volume":"35","author":"MG Wise","year":"2023","unstructured":"Wise MG, Karlowsky JA, Hackel MA, Harti MA, Ntshole BME, Njagua EN, et al. In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa from sub-Saharan Africa: ATLAS Global Surveillance Program 2017\u20132021. J Glob Antimicrob Resist. 2023;35:93\u2013100.","journal-title":"J Glob Antimicrob Resist"},{"issue":"9","key":"1518_CR145","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s10096-023-04645-2","volume":"42","author":"MG Wise","year":"2023","unstructured":"Wise MG, Karlowsky JA, Mohamed N, Kamat S, Sahm DF. In vitro activity of aztreonam-avibactam against Enterobacterales isolates collected in Latin America, Africa\/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019\u20132021. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2023;42(9):1135\u201343.","journal-title":"Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol"},{"key":"1518_CR146","doi-asserted-by":"crossref","unstructured":"Wu S, Yin D, Zhi P, Guo Y, Yang Y, Zhu D, et al. In Vitro Activity of MRX-8 and Comparators Against Clinical Isolated Gram-Negative Bacilli in China. 2022.","DOI":"10.3389\/fcimb.2022.829592"},{"key":"1518_CR147","doi-asserted-by":"publisher","first-page":"1198926","DOI":"10.3389\/fmicb.2023.1198926","volume":"14","author":"S Xiao","year":"2023","unstructured":"Xiao S, Fu Q, Miao Y, Zhao M, Lu S, Xu J, et al. Clinical efficacy and drug resistance of ceftazidime-avibactam in the treatment of Carbapenem-resistant gram-negative bacilli infection. Front Microbiol. 2023;14:1198926.","journal-title":"Front Microbiol"},{"issue":"8","key":"1518_CR148","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1093\/jpids\/piad055","volume":"12","author":"Q Yang","year":"2023","unstructured":"Yang Q, Kamat S, Mohamed N, Valdez RR, Lin S, Su M, et al. Antimicrobial Susceptibility Among Gram-Negative Isolates in Pediatric Patients in Latin America, Africa-Middle East, and Asia From 2016\u20132020 Compared to 2011\u20132015: Results From the ATLAS Surveillance Study. J Pediatric Infect Dis Soc. 2023;12(8):459\u201370.","journal-title":"J Pediatric Infect Dis Soc"},{"key":"1518_CR149","doi-asserted-by":"crossref","unstructured":"Yang Y, Guo Y, Yin D, Zheng Y, Wu S, Zhu D, et al. In Vitro Activity of Cefepime-Zidebactam, Ceftazidime-Avibactam, and Other Comparators against Clinical Isolates of Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii: Results from China Antimicrobial Surveillance Network (CHINET) in 2018. Antimicrobial agents and chemotherapy. 2020;65(1).","DOI":"10.1128\/AAC.01726-20"},{"key":"1518_CR150","doi-asserted-by":"crossref","unstructured":"Yin D, Wu S, Yang Y, Shi Q, Dong D, Zhu D, et al. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the In Vitro Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa. 2019.","DOI":"10.1128\/AAC.02431-18"},{"key":"1518_CR151","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.780365","volume":"11","author":"W Yu","year":"2021","unstructured":"Yu W, Xiong L, Luo Q, Chen Y, Ji J, Ying C, et al. In Vitro Activity comparison of ceftazidime-avibactam and aztreonam-avibactam against bloodstream infections with carbapenem-resistant organisms in China. Front Cell Infect Microbiol. 2021;11: 780365.","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"1518_CR152","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13756-020-00829-z","volume":"9","author":"H Zhang","year":"2020","unstructured":"Zhang H, Xu Y, Jia P, Zhu Y, Zhang G, Zhang J, et al. Global trends of antimicrobial susceptibility to ceftaroline and ceftazidime-avibactam: a surveillance study from the ATLAS program (2012\u20132016). Antimicrob Resist Infect Control. 2020;9(1):166.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"7","key":"1518_CR153","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jiac.2024.01.007","volume":"30","author":"S Zhen","year":"2024","unstructured":"Zhen S, Lin Q, Chen Z, Shen Y, Chen X, Pang A, et al. Ceftazidime-avibactam in the treatment of bacteremia due to carbapenem-resistant gram-negative bacteria in hematological patients: Experience in a single center. J Infect Chemother Off J Jpn Soc Chemother. 2024;30(7):608\u201315.","journal-title":"J Infect Chemother Off J Jpn Soc Chemother"},{"key":"1518_CR154","doi-asserted-by":"crossref","unstructured":"Zhuang H-H, Qu Q, Long W-M, Hu Q, Wu X-L, Chen Y, et al. Ceftazidime\/avibactam versus polymyxin B in carbapenem-resistant Klebsiella pneumoniae infections: a propensity score-matched multicenter real-world study. Infection. 2024:1\u201312.","DOI":"10.1007\/s15010-024-02324-8"},{"issue":"3","key":"1518_CR155","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1556\/030.2023.02108","volume":"70","author":"S Zornic","year":"2023","unstructured":"Zornic S, Petrovic I, Lukovic B. In vitro activity of imipenem\/relebactam and ceftazidime\/avibactam against carbapenem-resistant Klebsiella pneumoniae from blood cultures in a University hospital in Serbia. Acta Microbiol Immunol Hung. 2023;70(3):187\u201392.","journal-title":"Acta Microbiol Immunol Hung"},{"key":"1518_CR156","doi-asserted-by":"crossref","unstructured":"Zou C, Wei J, Shan B, Chen X, Wang D, Niu S. In vitro activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against Carbapenem-resistant Enterobacteriaceae isolates collected from three secondary hospitals in Southwest China Between 2018 and 2019. Infection and Drug Resistance. 2020:3563-8.","DOI":"10.2147\/IDR.S273989"},{"key":"1518_CR157","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s15010-017-1096-y","volume":"46","author":"FF Tuon","year":"2018","unstructured":"Tuon FF, Rocha JL, Formigoni-Pinto MR. Pharmacological aspects and spectrum of action of ceftazidime\u2013avibactam: a systematic review. Infection. 2018;46:165\u201381.","journal-title":"Infection"},{"issue":"3","key":"1518_CR158","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2022.106633","volume":"60","author":"SS Kanj","year":"2022","unstructured":"Kanj SS, Bassetti M, Kiratisin P, Rodrigues C, Villegas MV, Yu Y, et al. Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections. Int J Antimicrob Agents. 2022;60(3): 106633.","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"1518_CR159","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s40265-017-0725-1","volume":"77","author":"D Wong","year":"2017","unstructured":"Wong D, Van Duin D. Novel beta-lactamase inhibitors: unlocking their potential in therapy. Drugs. 2017;77(6):615\u201328.","journal-title":"Drugs"},{"issue":"5","key":"1518_CR160","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.jiph.2019.11.008","volume":"13","author":"A Pal","year":"2020","unstructured":"Pal A, Tripathi A. 4-Chloromercuribenzoic acid enhances carbapenem sensitivity among pathogenic Gram negative bacteria by altering blaVIM, adeB and ompC expression. J Infect Public Health. 2020;13(5):806\u201314.","journal-title":"J Infect Public Health"},{"issue":"1","key":"1518_CR161","first-page":"95","volume":"124","author":"E Gupta","year":"2006","unstructured":"Gupta E, Mohanty S, Sood S, Dhawan B, Das BK, Kapil A. Emerging resistance to carbapenems in a tertiary care hospital in north India. Indian J Med Res. 2006;124(1):95\u20138.","journal-title":"Indian J Med Res"},{"issue":"7","key":"1518_CR162","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1099\/jmm.0.000508","volume":"66","author":"P Manohar","year":"2017","unstructured":"Manohar P, Shanthini T, Ayyanar R, Bozdogan B, Wilson A, Tamhankar AJ, et al. The distribution of carbapenem-and colistin-resistance in Gram-negative bacteria from the Tamil Nadu region in India. J Med Microbiol. 2017;66(7):874\u201383.","journal-title":"J Med Microbiol"},{"key":"1518_CR163","doi-asserted-by":"publisher","unstructured":"Castanheira M, Huband MD, Mendes RE, Flamm RK. Meropenem-vaborbactam tested against contemporary Gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae. Antimicrobial agents and chemotherapy. 2017. https:\/\/doi.org\/10.1128\/aac.00567-17.","DOI":"10.1128\/aac.00567-17"},{"issue":"5","key":"1518_CR164","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.ijantimicag.2017.01.010","volume":"49","author":"X Qin","year":"2017","unstructured":"Qin X, Tran BG, Kim MJ, Wang L, Nguyen DA, Chen Q, et al. A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia. Int J Antimicrob Agents. 2017;49(5):579\u201388.","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"1518_CR165","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.3390\/antibiotics11111456","volume":"11","author":"I Lopez-Montesinos","year":"2022","unstructured":"Lopez-Montesinos I, Montero MM, Domene-Ochoa S, L\u00f3pez-Causap\u00e9 C, Echeverria D, Sorl\u00ed L, et al. Suboptimal concentrations of ceftazidime\/avibactam (CAZ-AVI) may select for CAZ-AVI resistance in extensively drug-resistant Pseudomonas aeruginosa: in vivo and in vitro evidence. Antibiotics. 2022;11(11):1456.","journal-title":"Antibiotics"},{"issue":"6","key":"1518_CR166","doi-asserted-by":"publisher","DOI":"10.1002\/wsbm.1571","volume":"14","author":"L Xiong","year":"2022","unstructured":"Xiong L, Wang X, Wang Y, Yu W, Zhou Y, Chi X, et al. Molecular mechanisms underlying bacterial resistance to ceftazidime\/avibactam. WIREs Mech Dis. 2022;14(6): e1571.","journal-title":"WIREs Mech Dis"},{"issue":"11","key":"1518_CR167","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1017\/ice.2016.174","volume":"37","author":"LM Weiner","year":"2016","unstructured":"Weiner LM, Webb AK, Limbago B, Dudeck MA, Patel J, Kallen AJ, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011\u20132014. Infect Control Hospital Epidemiol. 2016;37(11):1288\u2013301.","journal-title":"Infect Control Hospital Epidemiol"},{"issue":"39","key":"1518_CR168","doi-asserted-by":"publisher","first-page":"27960","DOI":"10.1074\/jbc.M113.485979","volume":"288","author":"J Thresher","year":"2013","unstructured":"Thresher J, Livchak S, Gao N, Palmer T, Walkup GK, Fisher SL. Kinetics of Avibactam Inhibition against Class A, C, and D-Lactamases. J Biol Chem. 2013;288(39):27960\u201371.","journal-title":"J Biol Chem"},{"key":"1518_CR169","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.01295-19","author":"C-C Su","year":"2019","unstructured":"Su C-C, Morgan CE, Kambakam S, Rajavel M, Scott H, Huang W, et al. Cryo-electron microscopy structure of an Acinetobacter baumannii multidrug efflux pump. MBio. 2019. https:\/\/doi.org\/10.1128\/mbio.01295-19.","journal-title":"MBio"},{"issue":"38","key":"1518_CR170","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2203593119","volume":"119","author":"JL Wong","year":"2022","unstructured":"Wong JL, David S, Sanchez-Garrido J, Woo JZ, Low WW, Morecchiato F, et al. Recurrent emergence of Klebsiella pneumoniae carbapenem resistance mediated by an inhibitory ompK36 mRNA secondary structure. Proc Natl Acad Sci. 2022;119(38): e2203593119.","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"1518_CR171","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","volume":"18","author":"E Tacconelli","year":"2018","unstructured":"Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318\u201327.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"1518_CR172","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1093\/jac\/dkz456","volume":"75","author":"I Spiliopoulou","year":"2020","unstructured":"Spiliopoulou I, Kazmierczak K, Stone GG. In vitro activity of ceftazidime\/avibactam against isolates of carbapenem-non-susceptible Enterobacteriaceae collected during the INFORM global surveillance programme (2015\u201317). J Antimicrob Chemother. 2020;75(2):384\u201391.","journal-title":"J Antimicrob Chemother"},{"key":"1518_CR173","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jgar.2021.08.010","volume":"27","author":"P Kiratisin","year":"2021","unstructured":"Kiratisin P, Kazmierczak K, Stone GG. In vitro activity of ceftazidime\/avibactam and comparators against carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa isolates collected globally between 2016 and 2018. J Glob Antimicrob Resist. 2021;27:132\u201341.","journal-title":"J Glob Antimicrob Resist"},{"key":"1518_CR174","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11908-015-0510-9","volume":"18","author":"K Chiotos","year":"2016","unstructured":"Chiotos K, Han JH, Tamma PD. Carbapenem-resistant Enterobacteriaceae infections in children. Curr Infect Dis Rep. 2016;18:1\u201311.","journal-title":"Curr Infect Dis Rep"},{"issue":"6","key":"1518_CR175","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1093\/jac\/dkv004","volume":"70","author":"SD Lahiri","year":"2015","unstructured":"Lahiri SD, Walkup GK, Whiteaker JD, Palmer T, McCormack K, Tanudra MA, et al. Selection and molecular characterization of ceftazidime\/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC. J Antimicrob Chemother. 2015;70(6):1650\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"1518_CR176","doi-asserted-by":"crossref","unstructured":"Fr\u00f6hlich C, S\u00f8rum V, Thomassen AM, Johnsen PJ, Leiros H-KS, Samuelsen \u00d8. OXA-48-mediated ceftazidime-avibactam resistance is associated with evolutionary trade-offs. Msphere. 2019;4(2):e00024\u201319.","DOI":"10.1128\/mSphere.00024-19"},{"key":"1518_CR177","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01117-17","author":"PA Fraile-Ribot","year":"2017","unstructured":"Fraile-Ribot PA, Mulet X, Cabot G, del Barrio-Tofi\u00f1o E, Juan C, P\u00e9rez JL, et al. In vivo emergence of resistance to novel cephalosporin\u2013\u03b2-lactamase inhibitor combinations through the duplication of amino acid D149 from OXA-2 \u03b2-lactamase (OXA-539) in sequence type 235 Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2017. https:\/\/doi.org\/10.1128\/aac.01117-17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"1518_CR178","doi-asserted-by":"publisher","first-page":"628","DOI":"10.3390\/antibiotics11050628","volume":"11","author":"P Gaibani","year":"2022","unstructured":"Gaibani P, Giani T, Bovo F, Lombardo D, Amadesi S, Lazzarotto T, et al. Resistance to ceftazidime\/avibactam, meropenem\/vaborbactam and imipenem\/relebactam in Gram-Negative MDR bacilli: molecular mechanisms and susceptibility testing. Antibiotics (Basel). 2022;11(5):628.","journal-title":"Antibiotics (Basel)"},{"key":"1518_CR179","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00846-21","author":"A Khan","year":"2021","unstructured":"Khan A, Erickson SG, Pettaway C, Arias CA, Miller WR, Bhatti MM. Evaluation of susceptibility testing methods for aztreonam and ceftazidime-avibactam combination therapy on extensively drug-resistant gram-negative organisms. Antimicrob Agents Chemother. 2021. https:\/\/doi.org\/10.1128\/aac.00846-21.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Antimicrobial Resistance &amp; Infection Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13756-025-01518-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13756-025-01518-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13756-025-01518-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T10:32:23Z","timestamp":1739442743000},"score":1,"resource":{"primary":{"URL":"https:\/\/aricjournal.biomedcentral.com\/articles\/10.1186\/s13756-025-01518-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":179,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1518"],"URL":"https:\/\/doi.org\/10.1186\/s13756-025-01518-5","relation":{},"ISSN":["2047-2994"],"issn-type":[{"value":"2047-2994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,11]]},"assertion":[{"value":"18 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}